

Running title: IL-17 promotes proliferation via LINC01518/miR-20a-5p/E2F1

IL-17 promotes H1299 cell proliferation via LINC01518/miR-20a-5p/E2F1 axis in non-small cell lung cancer

Chenhui Zhao^{1,2#}, Yuting Ruan^{3,4#}, Junjin Liao^{3,4}, Shuai Ying^{3,4}, Ningxia Wu^{3,4}, Pei Ma^{1,2}, Jing Wu^{1,2}, Yingwei Wang^{3,4}, Yongqian Shu^{1,2,*}, Wen Qiu^{3,4,*}

¹Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China; ²Jiangsu Key Laboratory of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, China; ³Department of Immunology, Nanjing Medical University, Nanjing, China; ⁴Key Laboratory of Immunological Environment and Disease, Nanjing Medical University, Nanjing, China

*Correspondence: shuyqtg@126.com; qiuwen@njmu.edu.cn

#Contributed equally to this work.

Received November 11, 2025 / Accepted May 22, 2026

Human non-small cell lung cancer (NSCLC) is an inflammation-related disease. Although IL-17-induced NSCLC cell proliferation that can be regulated by transcription factors has been demonstrated, the role and mechanism of other regulatory molecules, such as long noncoding RNAs (lncRNAs), in cell proliferation remains unclear. In this study, we screened and verified the expression of aberrant lncRNAs in NSCLC cell lines (H1299 and PC9) stimulated with IL-17, and found that LINC01518 was not only overexpressed, but also enhanced cell proliferation through IL-17/IL-17RA. Further mechanism investigation discovered that IL-17-upregulated LINC01518 was mainly localized in the cytoplasm, and it could combine with miR-20a-5p through a "sponge" function, decreasing miR-20a-5p induction, while LINC01518 and miR-20a-5p co-overexpression could partially reverse the cell proliferation mediated by LINC01518 alone. LINC01518 increase or miR-20a-5p decrease could elevate E2F1 level boosting H1299 cell proliferation exposed to IL-17, while miR-20a-5p and E2F1 co-overexpression partially restored the cell proliferation inhibition from miR-20a-5p upregulation. Besides, the xenograft tumor experiments of mice confirmed that LINC01518 overexpression indeed promoted tumor growth, cell proliferation, miR-20a-5p downregulation, and E2F1 upregulation. While LINC01518 knockdown reduced tumor growth, cell proliferation, miR-20a-5p downregulation, and E2F1 upregulation induced by IL-17 stimulation. Taken together, these findings reveal that the LINC01518/miR-20a-5p/E2F1 axis contributes to IL-17-induced cell proliferation in NSCLC.

Key words: NSCLC; IL-17; proliferation; LINC01518; miR-20a-5p; E2F1

Non-small cell lung cancer (NSCLC), accounting for more than 85% of all lung cancer cases, is the most contributor to cancer mortality worldwide [1-3]. Many researches have reported that NSCLC tumorigenesis and progression are associated with the overexpression of some cytokines or

mediators, and the upregulation of these factors in NSCLC microenvironment can induce the cancer cell proliferation, migration, invasion, including other changes such as T cell or NK cell reaction [4-7]. Our previous studies have disclosed that interleukin (IL)-17, as a pro-inflammatory cytokine, can enhance NSCLC cell proliferation and metastasis, and the underlying mechanism is involved in the transcriptional regulation or protein posttranslational modifications (PTMs) in IL-17-stimulated NSCLC cells [8-10]. However, the other regulative mechanism about IL-17-induced NSCLC cell proliferation has not been illuminated.

Long noncoding RNAs (lncRNAs) are classes of long-length (> 200 nucleotides) nonprotein-coding RNAs (ncRNAs) [11,12]. Numerous documents have showed that aberrantly expressed lncRNAs can modulate the proliferation of various cancer cells, including NSCLC [12-17], and some lncRNAs are recognized as cancer promoter or suppressor in cancer progression [18-20]. Furthermore, the mechanism studies have found that mostly upregulated lncRNAs can act as competing endogenous RNAs (ceRNAs) combining with some microRNAs (miRNAs) via a "sponge" function, which can reduce target gene inhibition mediated by miRNA causing the behavior alteration of cancer cells [21-23]. For instance, lncRNA LINC00665 can promote ovarian cancer (OC) cell proliferation by targeting miR-181a-5p/FHDC [12], and lncRNA PSMA3-AS1 enhances NSCLC progression through targeting miR-17-5p/PD-L1 [14], as well as lncRNA DLGAP1-AS1 can boost cell proliferation in hepatocellular carcinoma (HCC) via sequestering miR-486-5p [21]. Because up to now, little is known about whether some lncRNAs participate in the process of IL-17-triggered NSCLC cell proliferation, we thus attempt to find the abnormal lncRNAs for exploring their role and mechanism in IL-17-induced NSCLC cell proliferation.

miRNAs that belong to single-stranded short RNAs with short lengths (approximately 19-24 nucleotides) can negatively modulate target gene expression, which involves in miRNA binding to target mRNA at 3' UTR to mediate post-transcriptional gene silence or target mRNA translational repression, including degradation [24-26]. For example, LINC01518 can regulate the proliferation and migration in TGF- β 1-treated human tenon capsule fibroblast cells via hsa-miR-216b-5p [22], and lncRNA SNHG17 can impact the cell proliferation and invasion by targeting miR-338-3p/SOX4 in esophageal squamous cell carcinoma (ESCC) [23]. Besides, lncRNA BBOX1-AS1 also regulates the miR-382-5p/CBX3 pathway to affect the proliferation of glioblastoma cells [27]. These mentioned-above documents suggest that the interaction of lncRNA-miRNA-mRNA plays an important role in cancer cell proliferation. Nevertheless, although lncRNA-miRNA-mRNA in the cell proliferation from different cancers has been demonstrated [27-30], whether exists the similar axis in IL-17-mediated NSCLC cell proliferation is still elusive.

To response this problem mentioned-above, in this study, we first screened differentially expressed

lncRNAs in NSCLC cells lines (H1299 and PC9) stimulated with IL-17 for 3h by high-throughput sequencing. Then, we validated markedly ten elevated lncRNAs that has been proved to possess pro-proliferative function [11, 13, 14, 17, 21, 26, 27, 31-33]. Next, we chose the upregulated LINC01518 to explore its function and regulatory mechanism in IL-17-induced NSCLC cell proliferation.

Materials and methods

Cell lines, antibodies, reagents and animals. Human BEAS-2B bronchial epithelial cell line and NSCLC cell lines such as PC9, H1299 and H1975 were purchased from American Type Culture Collection (ATCC) or European Collection of Authenticated Cell Cultures (ECACC). Anti-IL-17RA (#ab180904), anti-E2F1 (#A2067) and anti-Ki67 (#A20018) Abs were supplied by Abcam (Cambridge, UK) or ABclonal Biotech (Wuhan, China). Anti-ARHGAP12 (#PA5-51384) Ab was from Thermo Fisher Scientific (Waltham, MA, USA). Anti-TSG101 (#28283-1-AP) and anti-CDKN1A (#10355-1-AP) Abs were purchased by Proteintech (Wuhan, China). HRP-conjugated anti-rabbit IgG (#BL003A) and HRP-conjugated anti-mouse IgG (#BL001A) were from Biosharp Biotech (Hefei, China). Anti- β -actin (#AF0003), RIPA lysis buffer (#P0013B) and BCA assay kit (#P0012) were provided by Beyotime Biotech (Beijing, China). Recombinant human IL-17A (#317-ILB-050) was provided by R&D Systems (Minneapolis, MN, USA). Lipofectamine 2000 (#11668019), PARISTM kit protein and RNA isolation system (AM1921) were from Thermo Fisher Scientific (Waltham, MA, USA). RNA isolater total RNA extraction reagent (#R401-01), HiScript II Q RT SuperMix for qPCR (#R222-01), 2 $\times$ Taq Plus Master Mix (#P212-01), AceQ qPCR SYBR Green Master Mix (#Q141-02) and cell counting kit-8 (CKK-8, #A311-01) were purchased from Vazyme Biotech (Nanjing, China). Cell-LightTM EdU Apollo[®]567 kit (#C10310-1), crystal violet (#548-62-9), anti-LINC01518, anti-U6 (#lnc110101) and anti-18s (#lnc110102) oligodeoxynucleotide probes were provided by Sigma-Aldrich (St. Louis, MO, USA) or RiboBio (Guangzhou, China). The dual-luciferase reporter assay kit (#E1910) was from Promega (Madison, WI, USA). Male BALB/c nude mice (4-5 weeks-old) were purchased from the Animal Core facility of Nanjing Medical University.

Cell culture and IL-17 stimulation. Cells were seeded into a 60 mm dish (8×10^5 cells/dish) and incubated in Dulbecco's Modified Eagle's Medium (DMEM) with 10% fetal bovine serum (FBS) at 37 °C containing 5% CO₂. When the cell density reached 80-90%, 50 ng/ml IL-17 in according to our previous experiments [8-10] was added to the cells for the fixed time (i.e., 1 h, 2 h, 3 h, 6 h, 12 h, or 48 h, 72 h, 96 h, 8 d) after the cells were starved for 24 h.

Plasmid construction and cell transfection. The full-length of human LINC01518 (NR_120659.1)

sequence or the open reading frame (ORF) of E2F1 cDNA (NM_005225.3) were synthesized and subcloned into pcDNA3.1 vector by General Biotech (Chuzhou, China). The shRNA plasmids were constructed via cloning target sequences (Table S2) into pGPU6/GFP/Neo. SiIL-17RA and pIRES2-IL-17RA plasmids were prepared by GenePharma (Shanghai, China) and General Biotech (Chuzhou, China), respectively. Moreover, miR-20a-5p mimic or inhibitor and the matched negative controls were synthesized by RiboBio, and the sequences were: miR-20a-5p mimic forward oligos, 5'-UAAAGUGCUUAUAGUGCAGGUAG-3'; miR-20a-5p mimic reverse oligos, 5'-CUACCUGCACUAUAAGCACUUUA-3'; miR-20a-5p inhibitor oligos, 5'-CUACCUGCACUAUAAGCACUUUA-3'. All plasmids (1 µg/ml), miR-20a-5p mimic (50 nM) and miR-20a-5p inhibitor (100 nM) were transfected into cells with Lipofectamine 2000 for 48 h, and the cells transfected shRNA for 48 h were followed by 50 ng/ml IL-17 for the corresponding time.

LncRNA high-throughput sequencing. The lysates from IL-17-stimulated or -unstimulated H1299 and PC9 cells for 3 h were mixed, then sent to Bohao Biotech (Shanghai, China) for LncRNA high-throughput sequencing. The sequencing results were analyzed and partly up-regulated LncRNAs were verified.

Reverse transcription-polymerase chain reaction (RT-PCR). Cell RNA was extracted by total RNA extraction reagent. 500 µg RNA, 2 µl HiScript II Q RT SuperMix for PCR and DEPC water were mixed for converting RNA into cDNA. Thereafter, PCR assay was performed on an ABI 2720 thermal cycler with 95 °C for 5 min followed by 35 cycles of denaturation at 94 °C for 30 sec, annealing at 60 °C for 30 sec and extension at 72 °C for 30 sec, finally repetitive extension at 72 °C for 7 min. The amplification products were analyzed by agarose gel electrophoresis. GAPDH was used as an internal control, and the primer sequences are shown in Supplementary Table S1.

Real time quantitative PCR (qPCR). The qPCR was carried out using AceQ qPCR SYBR Green Master Mix on an ABI 7300 system under 95 °C/5 min, 40 cycles of 95 °C/10 sec and 60 °C/30 sec, 95 °C/15 sec, 60 °C/30 sec, 95 °C/15 sec. The results were normalized to β-actin, and the primer sequences were also listed in Table S1. Besides, miR-20a-5p expression was determined by stem-loop RT-qPCR and U6 was used as an endogenous control. The primer sequence is: miR-20a-5p, stem-loop RT, 5'-GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACCTACCT-3', forward, 5'-GCGCGTAAAGTGCTTATAGTGC-3', reverse, 5'-AGTGCAGGGTCCGAGGTATT-3'. The qPCR results were analyzed using the $2^{-\Delta\Delta Ct}$ method.

Western blot (WB). Total protein was extracted from the cells and tumor tissues using RIPA lysis buffer and measured by BCA assay kit. Then equal quantities of protein (30 µg/lane) were subjected

151 to 10% SDS-PAGE gel and electro-transferred onto polyvinylidene fluoride (PVDF) membrane
152 from Millipore (Bedford, MA, USA). Subsequently, the membranes were blocked with 5% milk
153 and incubated with the Abs against IL-17RA, or E2F1 (dilution 1:1,000) overnight followed by
154 HRP-conjugated anti-rabbit and anti-mouse IgG (dilution 1:10,000) for 40 min. Immunolabelling
155 was visualized by enhanced chemiluminescent (ECL) system, and band intensities were quantified
156 by densitometry using Quantity One software (Bio-Rad, Hercules, CA, USA).

157 **CCK-8 test.** The cells were transfected with different plasmids for 48 h followed by with or
158 without IL-17 (50 ng/ml) stimulation for the fixed time (24 h, or 48 h, 72 h, 96 h). Afterwards, the
159 cells were incubated with 10 μ l CCK-8 reagent for 1 h, and the optical density (OD) was measured
160 at 450 nm at a wavelength of 450 nm using Synergy HTX multi-mode reader (Bio-Tek, Burlington,
161 VT, USA). Triplicate wells were assayed for each experiment, and the actual OD values were
162 obtained by subtracting the OD values of blank control group from the average OD values of each
163 group.

164 **Ethynyldeoxyuridine (EdU) assay.** The cell proliferation was determined with a Cell-Light™ EdU
165 Apollo®567 kit. Briefly, the cells were incubated with 100 μ l EdU (10 μ M) for 2 h plus 4%
166 paraformaldehyde for 40 min, permeabilized in 0.5% Triton X-100 for 10 min, and stained with
167 Apollo fluorescent dye solution for 30 min. Then, the cell nuclei were stained with 5 μ g/ml Hoechst
168 staining for 30 min. Images were observed and captured by a fluorescence microscope. The cell
169 proliferation (at 48 h and 72 h after 50 ng/ml IL-17 treatment) was evaluated by calculating the
170 ratios of EdU-positive cells to total cells (Hoechst-positive cells).

171 **Colony formation assay.** Cells were seeded as 300 cells/35 mm cultured dish with DMEM, and
172 treated with the same methods as CCK8 test. Next, the cells culture medium was changed every 3 d.
173 After the visible cell clones were observed at 8 d, the cells were fixed with methanol for 20 min
174 plus 0.1% crystal violet staining for 20 min, and the number of cell clones upon IL-17 for 8 d was
175 counted by naked eyes.

176 **Cytoplasmic and Nuclear fractionation.** Cytoplasmic and nuclear RNA was exacted by PARIS™
177 kit protein and RNA isolation system according to the manufacturer's instruction and reverse-
178 transcribed into cDNA. The LINC01518 expression in cytoplasm and nucleus exposed to IL-17 for
179 3 h was determined by qPCR (β -actin as a cytoplasmic control and U6 as a nuclear control).

180 **Fluorescence in situ hybridization (FISH).** Cells were fixed in 4% formaldehyde for 2 h and
181 permeabilized in 0.5% Triton X-100, as well as pre-hybridized for 30 min at 37 °C. Thereafter,
182 anti-LINC01518, anti-U6 and anti-18s oligodeoxynucleotide probes were added into the
183 hybridization solution at 37 °C overnight. Finally, the cells were counterstained with 4', 6-
184 diamidino-2-phenylindole (DAPI) and imaged using a confocal laser scanning microscope (Zeiss

185 LSM710, Germany). Besides, the percentage of signal in cytoplasm and nucleus was calculated by
186 ImageJ.

187 **Dual-luciferase reporter assay.** The potential sequence of miR-20a-5p binding site in LINC01518
188 was predicted using RNAhybrid (<https://bibiserv.cebitec.uni-bielefeld.de/rnahybrid>). Luciferase
189 plasmids containing the binding sequence (5'-
190 CTCCGTTTGGCAGCCACTTTTAATAAAGCATTTTTCCTG-3') and its mutant sequence (5'-
191 CTCCGTTTGGCAGCGTGATTTAATATTCGTAAAATCACTG-3') were synthesized by RiboBio,
192 termed as LINC01518-WT and LINC01518-Mut. Then, LINC01518-WT or LINC01518-Mut
193 plasmids along with miR-20a-5p mimic, or control mimic were respectively transfected into the cell
194 for 48 h. The relative luciferase activity was detected by a dual-luciferase reporter assay kit in
195 accordance to the kit's procedure, and expressed by the ratio of firefly fluorescence to renilla
196 luciferase fluorescence.

197 **Bioinformatics analysis.** TANRIC database
198 (https://ibl.mdanderson.org/tanric/_design/basic/main.html) was used to download LINC01518
199 expression in 488 NSCLC tissues and 58 paracancer tissues. InCAR database
200 (<https://lncar.renlab.org/explorer>) was employed to analyze the correlation between LINC01518
201 expression and 131 NSCLC patient's prognosis. LncBase (<https://diana.e-ce.uth.gr/lncbasev3/home>),
202 miRanda (<http://www.microrna.org/microrna/home.do>) and RNA22 (<https://cm.jefferson.edu/rna22/>)
203 were used to predict the miRNAs that could bind to LINC01518. StarBase
204 (<https://starbase.sysu.edu.cn/>), miRDB (<https://mirdb.org/>), mirDIP
205 (<https://ophid.utoronto.ca/mirDIP/index.jsp>) and TarBase (https://www.targetscan.org/vert_80/)
206 were used to analyze some target genes that could bind to miR-20a-5p. GEPIA2 database
207 (<https://gepia2.cancer-pku.cn>) was employed to show the expression level of E2F1, Rho GTPase-
208 activating protein 12 (ARHGAP12), tumor susceptibility 101 (TSG101) and cyclin-dependent
209 kinase inhibitor 1A (CDKN1A) in NSCLC and paracancer tissues. Besides, Kaplan-Meier Plotter
210 database (<https://kmplot.com/analysis/>) or StarBase database was analyzed the correlation between
211 these gene expression and NSCLC patient's prognosis, or predicted the site of miR-20a-5p binding
212 to E2F1.

213 **Lentiviral (Lv) packing and cell infection.** Lentivirus carrying LINC01518 gene or shLINC01518
214 (i.e., Lv-LINC01518, Lv-shLINC01518) and their control (i.e., Lv-empty, Lv-shCTR) were
215 prepared by Corues Biotechnology. For LV-shRNA infection, 2×10^5 H1299 cells were incubated
216 with above-mentioned lentivirus at the titer of 1×10^7 TU/ml for 48 h and then subjected to
217 selection with 2 μ g/ml puromycin.

218 **Animal experiment.** BALB/c nude mice were maintained under SPF conditions, and the animal

experiments in the study were approved by the Institutional Animal Care and Use Committee of Nanjing Medical University (IACUC-2507084). For xenograft model, H1299 cells (3×10^6 in 100 μ l PBS) stably infected with Lv-empty, Lv-LINC01518, Lv-shCTR or Lv-shLINC01518 were incubated with or without 50 ng/ml IL-17 for 3 h and respectively injected into the left dorsal flanks of BALB/c nude mice (n=5/group). Then, the tumor size was measured every 4 days using caliper from 8 d to 28 d. After 28 days, all mice were euthanized and sacrificed. The tumor was weighted and volume was calculated using the formula: $\text{length} \times \text{width}^2 \times 0.5$. Additionally, the tumor tissues were also used to PCR, WB and immunohistochemistry (IHC) assays for examining the corresponding parameters.

IHC detection. Paraffin sections (4 μ m thickness) of the tumor tissues were prepared. Briefly, the sections were repaired with sodium citrate buffer (pH 6.0) at 94 $^{\circ}$ C for 15 min, and then sealed with 1% BSA for 1 h, followed by primary anti-Ki67 Ab (1:1,000) at 4 $^{\circ}$ C overnight. Next, the sections were incubated with HRP-labeled anti-rabbit IgG at 37 $^{\circ}$ C for 30 min. After washing with PBS, the sections were immunostained by DAB reaction, and finally the photos were taken.

Statistical analysis. Data are presented as mean $\pm$ SE of three independent experiments. Statistical analysis was performed using SPSS 22.0 software (IBM Corporation, Armonk, New York, USA). Graphs were plotted using GraphPad Prism 8.0 software (San Diego, CA, USA). Student's t-test was used for comparing differences between two groups. One-way ANOVA was used for comparing differences among multiple groups and the S-N-K test was exploited for pairwise comparisons. $P < 0.05$ was considered statistically significant.

Results

NSCLC cell lines express IL-17RA and IL-17 can induce NSCLC cell proliferation. We examined IL-17RA level of NSCLC cell lines i.e., H1299, PC9 and H1975, including control BEAS-2B cell lines and found that these cells were all expressed IL-17RA, more in H1299 and PC9 cells (Supplementary Figure S1A). Then, to explore the role of IL-17 treatment in NSCLC cell proliferation, we stimulated H1299 and PC9 cells with 50 ng/ml IL-17 in accordance with our previous experiments [8-10] for the fixed time. The CCK8 and EdU assays showed that the proliferation levels of H1299 or PC9 cells at 24 h after IL-17 exposure were elevated, much more at 48 h and 72 h (Supplementary Figures S1B, S1C). Besides, the two cell colony numbers from colony formation test were also increased on the 8 d after IL-17 stimulation (Supplementary Figure S1D).

IL-17RA gene knockdown can reduce IL-17-mediated NSCLC cell proliferation. To make sure that IL-17-induced NSCLC cell proliferation is related to IL-17 binding to IL-17RA, we transfected

253 siIL-17RA into H1299 or PC9 cells for 48 h to silence IL-17RA (Figure 1A) followed by 50 ng/ml
254 IL-17 stimulation for 48 h, 72 h or 8 d. Thereafter, we detected the cell proliferation using the
255 above-mentioned assays and found that IL-17RA knockdown notably decreased the proliferation
256 levels of the two cells exposed to IL-17 (Figures 1B-1D). The data indicates that the proliferation of
257 H1299 and PC9 cells upon IL-17 needs IL-17 binding to IL-17RA.

258 **IL-17 stimulation increases LINC01518 expression in H1299 and PC9 cells.** To explore the
259 mechanism of H1299 and PC9 cell proliferation induced by IL-17, we performed lncRNA high-
260 throughput sequencing to examine differentially expressed lncRNAs in the two cell lines at 3 h after
261 50 ng/ml IL-17 treatment. The data displayed that there were numerous differentially expressed
262 lncRNAs, such as 459 upregulated (≥ 2 -fold) and 541 downregulated (≤ 2 -fold) lncRNAs
263 (Supplementary Figure S2A). Subsequently, we selected 10 lncRNAs (i.e., LINC01518,
264 LINC00265, PSMA3-AS1, LINC01347, DLGAP1-AS1, OIP5-AS1, SNHG17, NUTM2A-AS1,
265 LINC01194 and BBOX1-AS1), based on the upregulated lncRNAs, which has been reported to
266 possess pro-proliferative function in many literatures [11, 13, 14, 17, 21, 26, 27, 31-33]. Then, we
267 measured their expression level in the two cells stimulated with IL-17 for different time. The results
268 from RT-PCR and qPCR showed that the levels of LINC01518, LINC00265 and PSMA3-AS1 were
269 much elevated at 2 h, peaked 3 h among the 10 lncRNAs, especially more significant and stable of
270 LINC01518 in H1299 cells at 3 h (Supplementary Figures S2B, S2C). Thus, we chose LINC01518
271 to do further experiments.

272 **IL-17RA knockdown decrease LINC01518 expression and LINC01518 can promote IL-17-**
273 **induced cell proliferation.** To ascertain the effects of IL-17RA gene knockdown on IL-17-
274 upregulated LINC01518, we not only transfected siCTR or siIL-17RA into H1299 or PC9 cells for
275 48 h plus IL-17 incubation for 3 h (Supplementary Figure S3A), but also transfected siIL-17RA and
276 pIRES2-IL-17RA (to rescue IL-17RA knockdown caused by siIL-17RA) into the two cell lines for
277 48 h followed by IL-17 stimulation for 3 h (Figure 2A, 2B). The results demonstrated that silencing
278 IL-17RA gene markedly inhibited IL-17-induced LINC01518 increase, while silencing IL-17RA
279 followed by IL-17RA overexpression did not inhibit LINC01518 expression, particularly in H1299
280 cells. These data suggest that IL-17 stimulation can elevate LINC01518 expression via IL-17
281 binding to IL-17RA.

282 It has been confirmed that LINC01518 can participate in the progress of some diseases [22, 29],
283 hence we exploited TCGA and InCAR database to analyze relative parameters. The data from
284 TCGA showed that LINC01518 expression in 488 NSCLC tissues was significantly higher than that
285 in 58 paracancer tissues (Figure 2C), however only InCAR database manifested that higher level of
286 LINC01518 was closely associated with the poor prognosis of NSCLC patients (Figure 2D).

287 Because the lncRNA localization influences their function and cellular behavior [34], we next
288 observed LINC01518 localization in H1299 and PC9 cells by cytoplasmic-nuclear separation and
289 FISH experiments. The results exhibited that IL-17-upregulated LINC01518 mainly located in the
290 cytoplasm of H1299 and PC9 cells (Figures 2E-2G).

291 In order to clarify the role and mechanism of LINC01518 in regulating H1299 cells proliferation
292 induced by IL-17, we constructed and identified pcDNA3.1/LINC01518 (Supplementary Figure
293 S3B) or short hairpin RNAs (shLINC01518-1-3) plasmids (Supplementary Figure S3E). Afterwards,
294 we transfected pcDNA3.1 control or pcDNA3.1/LINC01518 plasmids into cells for 48 h, or
295 transfected shCTR control or shLINC01518-1-3 into the cells for 48 h followed by IL-17 for 3 h
296 (Supplementary Figures S3C, S3F). The results showed that pcDNA3.1/LINC01518 obviously
297 increased LINC01518 level (Supplementary Figure S3D), while shLINC01518-1 (termed as
298 shLINC01518) greatly inhibited LINC01518 expression in H1299 cells in response to IL-17
299 (Supplementary Figure S3G).

300 Next, we transfected the same plasmids described-previously into H1299 cells for 48 h plus IL-17
301 stimulation for 48 h, or 8 d to measure the cell proliferation. The assays of CCK8, EdU, or colony
302 formation displayed that LINC01518 overexpression improved H1299 cell proliferation, while
303 LINC01518 knockdown remarkably declined IL-17-induced cell proliferation (Figures 2H-2J).

304 **IL-17 stimulation or LINC01518 upregulation suppresses miR-20a-5p expression.** Given that
305 we have confirmed that IL-17-elevated LINC01518 is mostly located in the cytoplasm, the miRNAs
306 that can bind to LINC01518 should to be searched. Therefore, we first utilized LncBase, miRanda
307 and RNA22 databases to predict potential miRNAs and found that there were 6, 109 and 1028
308 miRNAs from the three databases respectively. Further Venn diagram showed that only miR-20a-5p
309 could combine with LINC01518 (Figure 3A), and RNAhybrid database exhibited the binding mfe is
310 - 17.1 kcal/mol (Figure 3B). These indicate that LINC01518 may be a sponge of miR-20a-5p.

311 Subsequently, we prepared and transfected miR-20a-5p mimic and miR-20a-5p inhibitor, including
312 the corresponding control into H1299 cells for 48 h, and demonstrated that the overexpression of
313 miR-20a-5p mimic or miR-20a-5p inhibitor could significantly increase or decrease miR-20a-5p
314 expression (Figures 3C, 3D). Then, we constructed the plasmids of wild-type (WT) and the site
315 mutant of binding miR-20a-5p (Mut) of LINC01518, namely LINC01518-WT and LINC01518-
316 Mut (Figures 3E, 3F), and co-transfected them with miR-20a-5p mimic or miR-20a-5p inhibitor
317 into H1299 cells for 48 h. The dual-luciferase reporter gene assay manifested that co-transfection of
318 miR-20a-5p mimic and LINC01518-WT obviously decreased the luciferase activity of LINC01518-
319 WT, but co-transfection of miR-20a-5p mimic and LINC01518-Mut did not have this change
320 (Figure 3G), implicating that miR-20a-5p can directly bind to the corresponding site of LINC01518.

Besides, to ensure that LINC01518 can regulate miR-20a-5p expression as a ceRNA, we stimulated H1299 cells with 50 ng/ml IL-17 for 1 h, 2 h, 3 h, and 6 h, or transfected pcDNA3.1/LINC01518 into H1299 cells for 48 h, or transfected shLINC01518 for 48 h plus IL-17 for 3 h. The data showed that IL-17 stimulation downregulated miR-20a-5p expression at 1 h, lower at 2 h, lowest at 3 h (Figure 3H), and LINC01518 overexpression also declined miR-20a-5p, but LINC01518 knockdown significantly reversed IL-17-induced miR-20a-5p reduction (Figure 3I).

miR-20a-5p downregulation enhances cell proliferation and LINC01518 plus miR-20a-5p overexpression can reverse LINC01518-promoted cell proliferation. To reveal the role of miR-20a-5p in regulating cell proliferation, we respectively transfected miR-20a-5p mimic or miR-20a-5p inhibitor, including the corresponding control into H1299 cells for 48 h or 8 d, and observed the change of cell proliferation. The results showed that miR-20a-5p overexpression or inhibition decreased or increased H1299 cell proliferation, respectively (Figures 4A-4C), suggesting that miR-20a-5p inhibition can promote the cell proliferation. Additionally, we also co-transfected pcDNA3.1 or pcDNA3.1/LINC01518 plasmids plus NC mimic or miR-20a-5p mimic into the cells for 48 h or 8 d, and demonstrated that only LINC01518 plus miR-20a-5p overexpression could partially reverse the increase of cell proliferation elevated by LINC01518 overexpression alone (Figures 4D-4F), indicating that LINC01518 upregulation can indeed promote H1299 cell proliferation via downregulating miR-20a-5p.

miR-20a-5p binds to E2F1 and IL-17 stimulation or miR-20a-5p inhibition can raise E2F1 level. Since that miR-20a-5p can bind to LINC01518 has been ascertained, the downstream target gene of miR-20a-5p requires to be determined. To address this, we used to the databases of StarBase, miRDB, mirDIP and TarBase to predict and intersect potential target genes. Database prediction confirmed that transcription factor E2F1, Rho GTPase-activating protein 12 (ARHGAP12), tumor susceptibility 101(TSG101), and cyclin dependent kinase inhibitor 1A (CDKN1A) could combine miR-20a-5p (Figure 5A). Afterwards, we exploited the database of GEPIA or Kaplan-Meier Plotter to analyze the expression of the four genes in NSCLC tissues as well as their correlation with NSCLC patients' prognosis. The data showed that only E2F1 expression in 483 NSCLC tissues was significantly higher than that of the 347 paracancer tissues (Figure 5B), and higher E2F1 level was along with poorer prognosis in 1925 NSCLC patients (Figure 5C). Then, we transfected miR-20a-5p mimic into H1299 cells for 48 h to observe the expression of these target genes. The data displayed that only the mRNA and protein of E2F1 were greatly decreased after miR-20a-5p overexpression (Figures 5D, 5E). Additionally, the binding site of miR-20a-5p on E2F1 was exhibited by StarBase database (Figure 5F). Furthermore, we stimulated H1299 cells with 50 ng/ml IL-17 for 1 h, 2 h, 3 h, 6 h and 12 h, or transfected miR-20a-

355 5p mimic or miR-20a-5p inhibitor into the cells for 48 h, and proved that IL-17 stimulation
356 increased E2F1 expression, remarkably at 2 h, and peaked at 3 h (Figure 5G). When miR-20a-5p
357 was overexpressed or inhibited, the mRNA and protein of E2F1 were downregulated or upregulated,
358 respectively (Figures 5H, 5I). These findings suggest that miR-20a-5p inhibition upon IL-17 can
359 notably elevate E2F1 level.

360 **LINC01518 increases E2F1 expression and E2F1, which acts as a direct downstream molecule**
361 **of miR-20a-5p, advances IL-17-induced cell proliferation.** At the beginning of experiment, we
362 constructed and identified pcDNA3.1/E2F1 or shE2F1 plasmids (Supplementary Figures S4A-S4H).
363 Then, we transfected pcDNA3.1/LINC01518 or pcDNA3.1/E2F1 into H1299 cells for 48 h, or
364 transfected shLINC01518 or shE2F1 for 48 h plus IL-17 for 3 h, 48 h, 8 d to investigate E2F1
365 expression at 3 h and cell proliferation at 48 h or 8 d. The results showed that LINC01518
366 overexpression increased E2F1 level, while LINC01518 gene knockdown effectively inhibited
367 E2F1 upregulation exposed to IL-17 (Figures 6A, 6B). Accordingly, overexpressed or silenced
368 E2F1 increased or decreased IL-17-stimulated cell proliferation, respectively (Figures 6C-6E).
369 Meantime, we co-transfected miR-20a-5p mimic and pcDNA3.1/E2F1 or control plasmids into
370 H1299 cells for 48 h, and found that co-overexpression of miR-20a-5p and E2F1 could partially
371 restore the suppression of cell proliferation mediated by miR-20a-5p mimic alone or miR-20a-5p
372 mimic plus pcDNA3.1 control (Figures 6F-6H). The data indicate that the changes of LINC01518,
373 miR-20a-5p or E2F1 level can impact IL-17-induced cell proliferation by indirect or direct manner.
374 Next, to further determine the upstream or downstream relationship between E2F1 and LINC01518
375 or miR-20a-5p, we respectively transfected pcDNA3.1, pcDNA3.1/E2F1 into H1299 cells for 48 h,
376 or transfected shCTR or shE2F1 into the cells for 48 h followed by IL-17 for 3 h. The results
377 exhibited that after E2F1 overexpression, the level of LINC01518 and miR-20a-5p did not
378 obviously alter, but in the cells with shCTR+IL-17 or shE2F1 + IL-17 treatment, the level of
379 LINC01518 was increased. Additionally, the level of miR-20a-5p was still decreased, while level of
380 LINC01518 and miR-20a-5p between the two groups (namely shCTR+IL-17 and shE2F1+IL-17)
381 had no significant difference (Figure 6I). These data confirm that E2F1 is a downstream molecule
382 of LINC01518 and miR-20a-5p in IL-17-stimulated H1299 cells.

383 **LINC01518 can promote tumor growth, cell proliferation and E2F1 expression of in mouse**
384 **xenograft model.** To evaluate the potential roles of LINC01518 in vivo, we subcutaneously
385 injected H1299 cells that had been stably infected with Lv-empty, Lv-LINC01518, Lv-shCTR, Lv-
386 shLINC01518 followed by IL-17 incubation into BALB/c nude mice to establish xenograft model.
387 The groups were as follows: Lv-empty, Lv-LINC01518, Lv-shCTR+IL-17 and Lv-
388 shLINC01518+IL-17 groups. After 28 d, the volume and weight of the tumors from Lv-LINC01518

389 or Lv-shLINC01518+IL-17 group were correspondingly much larger or smaller compared to Lv-
390 empty or Lv-shCTR+IL-17 group (Figures 7A-7C). Moreover, the markedly higher or lower Ki67
391 cells in the tumor tissue sections by IHC were seen in Lv-LINC01518 or Lv-shLINC01518+IL-17
392 group compared to Lv-empty or Lv-shCTR+IL-17 group (Figure 7D). Meanwhile, the upregulating
393 LINC01518, E2F1 and reducing miR-20a-5p, as well as decreasing LINC01518, E2F1 and
394 increasing miR-20a-5p of the tumor tissues in Lv-LINC01518 or Lv-shLINC01518+IL-17 was also
395 confirmed by qPCR and WB assays (Figures 7E-7G).

396

397 Discussion

398 LncRNAs have been widely identified and researched in diverse types of cancers, including
399 NSCLC [11-20]. Our former studies have confirmed that the progression of NSCLC partly
400 contributes to IL-17 overexpression, and the increased IL-17 in the cancer tissues can promote the
401 proliferation and invasion of NSCLC cells [8-10]. In the present study, we first screened and
402 validated the change of lncRNA expression in NSCLC cells (H1299 and PC9) stimulated with IL-
403 17 and found that many lncRNAs were markedly upregulated. Among these elevated lncRNAs,
404 LINC01518 exhibited higher level via IL-17 binding to IL-17RA on H1299 and PC9 cells.
405 Meantime, we further overexpressed or silenced LINC01518 gene in the two cells and proved that
406 LINC01518 upregulation or downregulation could correspondingly increase or decrease the
407 proliferation of H1299 and PC9 cells. These findings suggest that LINC01518 upregulation upon
408 IL-17 promotes NSCLC cell proliferation.

409 Previous documents have showed that LINC01518 has different roles in human diseases and
410 cancers [22, 29]. For example, Kong N and his colleagues [22] have reported that LINC01518 can
411 regulate the proliferation and migration in TGF- β 1-treated human tenon capsule fibroblast cells
412 through affecting hsa-miRNA-216b-5p, and Zhang D et al [29] have proposed that LINC01518
413 knockdown can weaken the tumorigenicity by suppression PIK3KCA/Akt pathway in OSCC.
414 However, up to date, the role and mechanism of LINC01518 in IL-17-induced NSCLC cell
415 proliferation remain largely unrecognized.

416 Several researches have noted that the function of lncRNAs is associated with its localization in
417 cellular nucleus or cytoplasm [11, 34]. The lncRNAs in cytoplasm can act as sponge for certain
418 miRNAs to impact cell behaviors, such as proliferation and migration [27-31]. Based on these
419 reports, in this study, we examined LINC01518 localization and demonstrated that IL-17-
420 upregulated LINC01518 was mostly located in the cytoplasm of H1299 and PC9 cells. Considering
421 that many lncRNAs can negatively modulate some miRNAs, we thus used several databases to
422 predict the miRNA that could combine with LINC01518. Thereafter, further experiments exhibited

that miR-20a-5p could directly interact with LINC01518, and its expression could be retrained by LINC01518 upregulation, indicating that LINC01518 can be as a sponge depressing miR-20a-5p induction in NSCLC cells exposed to IL-17.

In the progression of human diseases, miR-20a-5p expression can be decreased by competitively binding to lncRNA to influence the cellular functions [30, 31, 35, 36]. For instance, lncRNA FALEC can augment the cell proliferation, migration and drug resistance of cholangiocarcinoma through miR-20a-5p/SHOC2 axis [30], and lncRNA GALML3-AS1 suppresses papillary thyroid cancer via sponging miR-20a-5p/RBM38 [35]. Additionally, lncRNA HAGLR can also accelerate gastric cancer progression by affecting miR-20a-5p/E2F1 [36]. In our experiment, we found that miR-20a-5p expression was remarkably downregulated in H1299 cells stimulated by IL-17, and LINC01518 overexpression inhibited miR-20a-5p, and LINC01518 knockdown restored miR-20a-5p expression. Further investigation exhibited that LINC01518 could competitively combine with the corresponding sequence of miR-20a-5p suppressing miR-20a-5p production, which aggravated IL-17-triggered cell proliferation, while LINC01518 and miR-20a-5p co-overexpression, the H1299 cell proliferation was markedly lower compared with LINC01518 overexpression alone. These data implicate that LINC01518 can really enhance NSCLC cell proliferation via sponging miR-20a-5p.

As we have known, the regulatory axis of lncRNA-miRNA-mRNA contributes partly to the tumorigenesis and progression of various cancers [37-39]. Meng et al. [38] have demonstrated that LINC00461 can boost the expression of transcription factor E2F1 through sponging miR-4478, and LINC00461/miR-4478/E2F1 feedback loop can advance NSCLC cell proliferation and migration. In addition, Gobbi et al. [39] have reported that lncRNA TAZ-AS202 also promotes NSCLC progression via increasing E2F1, and Huang et al. [40] have confirmed that E2F1 can cause cancer malignant behaviors by regulating cell cycle, which is related to the crosstalk between lncRNA and E2F1. Thereby, in the study, we used several databases to predict the target gene of miR-20a-5p and performed next tests, and further results uncovered that IL-17 stimulation or miR-20a-5p inhibition in H1299 cells could significantly upregulate E2F1 level, and LINC01518 overexpression was accompanied with E2F1 increase. Meanwhile, E2F1 gene overexpression or knockdown obviously raised or reduced IL-17-induced H1299 cell proliferation, but E2F1 expression increase or decrease did not affect LINC01518 and miR-20a-5p induction mediated by IL-17. Notably, E2F1 overexpression could partially restore H1299 cell proliferation, which was inhibited by miR-20a-5p, indicating that E2F1 is a downstream factor of LINC01518 and miR-20a-5p in IL-17-stimulated H1299 cells. Additionally, the in vivo experiments of mouse xenograft tumor also proved that LINC01518 upregulation could promote tumor growth, cell proliferation, miR-20a-5p inhibition, and E2F1 expression.

To summarize, the study showed that IL-17 exposure to NSCLC cells could not only upregulate LINC01518 or E2F1 and downregulate miR-20a-5p expression, but also promote the cell proliferation via binding to IL-17RA. Mechanistically, IL-17-upregulated LINC01518 was mainly localized in the cytoplasm, and as a molecular sponge, LINC01518 could inhibit miR-20a-5p production and elevate E2F1 level via combining with miR-20a-5p, leading to increasing H1299 cell proliferation upon IL-17 (Figure 7H). Overall, these findings from the experiments in vitro and in vivo discover that IL-17-triggered NSCLC cell proliferation needs the formation of LINC01518/miR-20a-5p/E2F1 axis, which offers a new insight to the pathogenesis of NSCLC cell proliferation induced by IL-17 and several potential targets for NSCLC therapy.

Acknowledgements: This work was supported by the National Natural Science Foundation of China (No. 81902878). The study was also supported by the Excellent Young or Middle-aged Teachers Project of Nanjing Medical University. We thank all the participants for this work.

Supplementary information is available in the online version of the paper.

References

- [1] XU J, TIAN L, QI W, LV Q, WANG T. Advancements in NSCLC: From Pathophysiological Insights to Targeted Treatments. *Am J Clin Oncol* 2024; 47: 291-303. <https://doi.org/10.1097/coc.0000000000001088>
- [2] SUNG H, FERLAY J, SIEGEL RL, LAVERSANNE M, SOERJOMATARAM I et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin* 2021; 71: 209-249. <https://doi.org/10.3322/caac.21660>
- [3] BADE BC, DELA CRUZ CS. Lung Cancer 2020: Epidemiology, Etiology, and Prevention. *Clin Chest Med* 2020; 41: 1-24. <https://doi.org/10.1016/j.ccm.2019.10.001>
- [4] GRETEN F R, GRIVENNIKOV SI. Inflammation and Cancer: Triggers, Mechanisms, and Consequences. *Immunity* 2019; 51: 27-41. <https://doi.org/10.1016/j.immuni.2019.06.025>
- [5] LIU Y, GAO Y, LIN T. Expression of interleukin-1 (IL-1), IL-6, and tumor necrosis factor- α (TNF- α) in non-small cell lung cancer and its relationship with the occurrence and prognosis of cancer pain. *Ann Palliat Med* 2021; 10: 12759-12766. <https://doi.org/10.21037/apm-21-3471>
- [6] ZHAO C, LI Y, QIU W, HE F, ZHANG W et al. C5a induces A549 cell proliferation of non-small cell lung cancer via GDF15 gene activation mediated by GCN5-dependent KLF5 acetylation. *Oncogene* 2018; 37: 4821-4837. <https://doi.org/10.1038/s41388-018-0298-9>
- [7] GUO J, PENG L, MA P, MAI Y, GAO T et al. IL-15 functionalized biomimetic hybrid mRNA vaccine for enhanced NSCLC immunotherapy via synergistic activation of T cells and NK cells. *Mater Today Bio* 2025; 32: 101914. <https://doi.org/10.1016/j.mtbio.2025.101914>

- 497 [8] ZHAO C, LI Y, ZHANG W, ZHAO D, MA L et al. IL- 17 induces NSCLC A549 cell
498 proliferation via the upregulation of HMGA1, resulting in an increased cyclin D1
499 expression. *Int J Oncol* 2018; 52: 1579-1592. <https://doi.org/10.3892/ijo.2018.4307>
- 500 [9] GE W, GONG Y, LI Y, WU N, RUAN Y et al. IL-17 induces non-small cell lung cancer
501 metastasis via GCN5-dependent SOX4 acetylation enhancing MMP9 gene transcription and
502 expression. *Mol Carcinog* 2023; 62: 1399-1416. <https://doi.org/10.1002/mc.23585>
- 503 [10] GE W, LI Y A, RUAN Y, WU N, MA P et al. IL-17 induces NSCLC cell migration and
504 invasion by elevating MMP19 gene transcription and expression through the interaction of
505 p300-dependent STAT3-K631 acetylation and its Y705-phosphorylation. *Oncol Res* 2024;
506 32: 625-641. <https://doi.org/10.32604/or.2023.031053>
- 507 [11] GHAFOURI-FARD S, SHOOREI H, BRANICKI W, TAHERI M. Non-coding RNA profile
508 in lung cancer. *Exp Mol Pathol* 2020; 114: 104411.
509 <https://doi.org/10.1016/j.yexmp.2020.104411>
- 510 [12] WANG S, WANG Y, LU J, WANG J. lncRNA LINC00665 Promotes Ovarian Cancer Cell
511 Proliferation and Inhibits Apoptosis via Targeting miR-181a-5p/FHDC. *Appl Biochem*
512 *Biotechnol* 2022; 194: 3819-3832. <https://doi.org/10.1007/s12010-022-03943-3>
- 513 [13] MENG F, ZHOU Y, DONG B, DONG A, ZHANG J. Long non-coding RNA LINC01194
514 promotes the proliferation, migration and invasion of lung adenocarcinoma cells by targeting
515 miR-641/SETD7 axis. *Cancer Cell Int* 2020; 20: 588. <https://doi.org/10.1186/s12935-020-01680-3>
- 516 [14] CHENG G, LI Y, LIU Z, SONG X. lncRNA PSMA3-AS1 promotes the progression of non-
517 small cell lung cancer through targeting miR-17-5p/PD-L1. *Adv Clin Exp Med* 2021; 30:
518 1043-1050. <https://doi.org/10.17219/acem/138624>
- 519 [15] WANG W, WEI C, LI P, WANG L, LI W et al. Integrative analysis of mRNA and lncRNA
520 profiles identified pathogenetic lncRNAs in esophageal squamous cell carcinoma. *Gene*
521 2018; 661: 169-175. <https://doi.org/10.1016/j.gene.2018.03.066>
- 522 [16] HUA Q, JIN M, MI B, XU F, LI T et al. LINC01123, a c-Myc-activated long non-coding
523 RNA, promotes proliferation and aerobic glycolysis of non-small cell lung cancer through
524 miR-199a-5p/c-Myc axis. *J Hematol Oncol* 2019; 12: 91. <https://doi.org/10.1186/s13045-019-0773-y>
- 525 [17] KOTAKE Y, MATSUNAGA N, WAKASAKI T, OKADA R. OIP5-AS1 Promotes
526 Proliferation of Non-small-cell Lung Cancer and Head and Neck Squamous Cell Carcinoma
527 Cells. *Cancer Genomics Proteomics* 2021; 18: 543-548. <https://doi.org/10.21873/cgp.20279>
- 528 [18] OYUAN K, LAN J, XU L, FENG X, LIAO H et al. Long noncoding RNA TLNC1 promotes
529 the growth and metastasis of liver cancer via inhibition of p53 signaling. *Mol Cancer* 2022;
530 21: 105. <https://doi.org/10.1186/s12943-022-01578-w>
- 531 [19] ZHA LF, ZHANG LD, PAN HM, MA HD. Upregulation of lncRNA NCK1-AS1 predicts
532 poor prognosis and contributes to non-small cell lung cancer proliferation by regulating
533 CDK1. *Eur Rev Med Pharmacol Sci* 2021; 25: 1351-1357.
534 https://doi.org/10.26355/eurrev_202102_24843
- 535 [20] FANG D, OU X, SUN K, ZHOU X, LI Y et al. m6A modification-mediated lncRNA
536 TP53TG1 inhibits gastric cancer progression by regulating CIP2A stability. *Cancer Sci*
537 2022; 113: 4135-4150. <https://doi.org/10.1111/cas.15581>
- 538 [21] PENG X, WEI F, HU X. Long noncoding RNA DLGAP1-AS1 promotes cell proliferation in
539 hepatocellular carcinoma via sequestering miR-486-5p. *J Cell Biochem* 2020; 121: 1953-
540 1962. <https://doi.org/10.1002/jcb.29430>

- 543 [22] KONG N, BAO Y, ZHAO H, KANG X, TAI X et al. Long Noncoding RNA LINC01518
544 Modulates Proliferation and Migration in TGF- β 1-Treated Human Tenon Capsule Fibroblast
545 Cells Through the Regulation of hsa-miR-216b-5p. *Neuromolecular Med* 2022; 24: 88-96.
546 <https://doi.org/10.1007/s12017-021-08662-2>
- 547 [23] CHEN W, WANG L, LI X, ZHAO C, SHI L et al. LncRNA SNHG17 regulates cell
548 proliferation and invasion by targeting miR-338-3p/SOX4 axis in esophageal squamous cell
549 carcinoma. *Cell Death Dis* 2021; 12: 806. <https://doi.org/10.1038/s41419-021-04093-w>
- 550 [24] BUDAKOTI M, PANWAR AS, MOLPA D, SINGH RK, BÜSSELBERG D et al. Micro-
551 RNA: The darkhorse of cancer. *Cell Signal* 2021; 83: 109995.
552 <https://doi.org/10.1016/j.cellsig.2021.109995>
- 553 [25] HUANG W, WU X, XIANG S, QIAO M, CEN X et al. Regulatory mechanism of miR-20a-
554 5p expression in Cancer. *Cell Death Discov* 2022; 8: 262. <https://doi.org/10.1038/s41420-022-01005-5>
- 555 [26] WANG J, YU Z, WANG J, SHEN Y, QIU J et al. LncRNA NUTM2A-AS1 positively
556 modulates TET1 and HIF-1A to enhance gastric cancer tumorigenesis and drug resistance by
557 sponging miR-376a. *Cancer Med* 2020; 9: 9499-9510. <https://doi.org/10.1002/cam4.3544>
- 558 [27] TAN B, CHEN T, SONG P, LIN F, HE S et al. lncRNA BBOX1-AS1 regulates the miR-382-
559 5p/CBX3 Signalling pathway to affect the proliferation and apoptosis of glioblastoma cells.
560 *Int Immunopharmacol* 2025; 157: 114790. <https://doi.org/10.1016/j.intimp.2025.114790>
- 561 [28] PAN T, WANG H, WANG S, LIU F. Long Non-Coding RNA LINC01929 Facilitates Cell
562 Proliferation and Metastasis as a Competing Endogenous RNA Against MicroRNA miR-
563 1179 in Non-Small Cell Lung Carcinoma. *Br J Biomed Sci* 2022; 79: 10598.
564 <https://doi.org/10.3389/bjbs.2022.10598>
- 565 [29] ZHANG D, ZHANG H, WANG X, HU B, ZHANG F et al. LINC01518 knockdown inhibits
566 tumorigenicity by suppression of PIK3CA/Akt pathway in oesophageal squamous cell
567 carcinoma. *Artif Cells Nanomed Biotechnol* 2019; 47: 4284-4292.
568 <https://doi.org/10.1080/21691401.2019.1699815>
- 569 [30] DU H, HOU S, ZHANG L, LIU C, YU T et al. LncRNA FALEC increases the proliferation,
570 migration and drug resistance of cholangiocarcinoma through competitive regulation of
571 miR-20a-5p/SHOC2 axis. *Aging (Albany NY)* 2023; 15: 3759-3770.
572 <https://doi.org/10.18632/aging.204709>
- 573 [31] LI X, GUO C, CHEN Y, YU F. Long non-coding RNA SNHG16 regulates E2F1 expression
574 by sponging miR-20a-5p and aggravating proliferative diabetic retinopathy. *Can J Physiol*
575 *Pharmacol* 2021; 99: 1207-1216. <https://doi.org/10.1139/cjpp-2020-0693>
- 576 [32] YU S, CUI Z, ZHOU J, WANG K, LI Q et al. LINC00265 maintains hepatocyte
577 proliferation during liver regeneration by targeting miRNA-28-5p. *Biosci Biotechnol*
578 *Biochem* 2021; 85: 528-536. <https://doi.org/10.1093/bbb/zbaa049>
- 579 [33] ZHENG G, LIU Y, YAN Z, XIE X, Xiang Z et al. Elevated LOXL2 expression by
580 LINC01347/miR-328-5p axis contributes to 5-FU chemotherapy resistance of colorectal
581 cancer. *Am J Cancer Res* 2021; 11: 1572-1585.
- 582 [34] BRIDGES MC, DAULAGALA AC, KOURTIDIS A. LNCcation: lncRNA localization and
583 function. *J Cell Biol* 2021; 220. <https://doi.org/10.1083/jcb.202009045>
- 584 [35] ZHANG X, ZHANG X, JIA Q, LI H, MA R et al. LncRNA CALML3-AS1 suppresses
585 papillary thyroid cancer progression via sponging miR-20a-5p/RBM38 axis. *BMC Cancer*
586 2022; 22: 344. <https://doi.org/10.1186/s12885-022-09360-3>
- 587

- 588 [36] LIU Q, LI Y, TAN B, ZHAO Q, FAN L et al. LncRNA HAGLR regulates gastric cancer
589 progression by regulating the miR-20a-5p/E2F1 axis. *Aging (Albany NY)* 2024; 16: 11843-
590 11856. <https://doi.org/10.18632/aging.206039>
- 591 [37] SHETTY A, VENKATESH T, KABBEKODU SP, TSUTSUMI R, SURESH PS. LncRNA-
592 miRNA-mRNA regulatory axes in endometrial cancer: a comprehensive overview. *Arch*
593 *Gynecol Obstet* 2022; 306: 1431-1447. <https://doi.org/10.1007/s00404-022-06423-5>
- 594 [38] MENG Q, LIU M, CHENG R. LINC00461/miR-4478/E2F1 feedback loop promotes non-
595 small cell lung cancer cell proliferation and migration. *Biosci Rep* 2020; 40.
596 <https://doi.org/10.1042/bsr20191345>
- 597 [39] GOBBI G, GRIECO A, TORRICELLI F, SAUTA E, SANTANDREA G et al. The long non-
598 coding RNA TAZ-AS202 promotes lung cancer progression via regulation of the E2F1
599 transcription factor and activation of Ephrin signaling. *Cell Death Dis* 2023; 14: 752.
600 <https://doi.org/10.1038/s41419-023-06277-y>
- 601 [40] HUANG P, WEN F, LI Q. Current concepts of the crosstalk between lncRNA and E2F1:
602 shedding light on the cancer therapy. *Front Pharmacol* 2024; 15: 1432490.
603 <https://doi.org/10.3389/fphar.2024.1432490>
604

605 Figure Legends

606

607 **Figure 1.** The change of IL-17-induced H1299 and PC9 cell proliferation after IL-17RA silence. A)
608 IL-17RA expression in the cells transfected with siIL-17RA or siCTR for 48 h was detected by WB.
609 B, C) The levels of cell proliferation transfected with siIL-17RA plus IL-17 stimulation for 48 h and
610 72 h were measured by CCK8 (B) or EdU (C) assay (Magnification: $\times 200$). D) The cell colony
611 numbers in the cells transfected with siIL-17RA plus IL-17 treatment for 8 d were examined by
612 colony formation assay. Data were displayed as means $\pm$ SE (n=3), **p < 0.01 vs. siCTR; $\blacktriangle\blacktriangle$ p <
613 0.01 vs. siCTR+IL-17.

614

615 **Figure 2.** LINC01518 expression after silencing IL-17RA, TANRIC or InCAR database analysis,
616 and LINC01518 licolization, as well as LINC01518 role in cell proliferation. A) The expression of
617 IL-17RA in H1299 (up) and PC9 (down) cells transfected with pIRES2-EGFP or pIRES2-IL-17RA
618 was determined by WB. B) The RNA of LINC01518 in H1299 and PC9 cells transfected with
619 siCTR, siIL-17RA, pIRES2-EGFP or pIRES2-IL-17RA for 48 h plus IL-17 for 3 h was detected by
620 qPCR, **p < 0.01 vs. siCTR+pIRES2-EGFP; $\blacktriangle$ p < 0.05, $\blacktriangle\blacktriangle$ p < 0.01 vs. siCTR+pIRES2-
621 EGFP+IL-17. C) The level of LINC01518 expression was analyzed by TANRIC database, *p <
622 0.05 vs. normal control. D) The correlation between LINC01518 expression and NSCLC patient's
623 prognosis was analyzed by InCAR database. E) The cytoplasmic and nuclear levels of LINC01518
624 after IL-17 stimulation for 3 h were examined by qPCR (β -actin as cytoplasmic and U6 as nuclear
625 control). F) LINC01518 localization in H1299 and PC9 cells was determined by FISH (18S as
626 cytoplasmic and U6 as nuclear control). Magnification $\times 400$. G) The percentage levels of

627 LINC01518 in cytoplasm and nucleus in H1299 and PC9 cells from FISH experiments (F). H-J)
 628 The proliferation of H1299 cells respectively transfected with pcDNA3.1, pcDNA3.1/LINC01518
 629 for 48 h, or shCTR, shLINC01518 for 48 h followed by IL-17 48 h or 8 d were detected by CCK8
 630 (H), EdU (I, Magnification $\times 200$) or colony formation (J) assays. Data were presented as means $\pm$ SE
 631 (n=3), **p < 0.01 vs. pcDNA3.1, $\Delta\Delta$ p < 0.01 vs. shCTR, $\Delta\Delta$ p < 0.01 vs. shCTR+IL-17

632

633 **Figure 3.** Identification of LINC01518 binding to miRNA, and effects of IL-17 stimulation and
 634 LINC01518 overexpression or knockdown on miR-20a-5p induction. A) The potential miRNAs that
 635 can bind to LINC01518 were predicted by LncBase, miRanda and RNA22 databases. B) Sketch
 636 map of LINC01518 combined with miR-20a-5p site that was predicted by RNAhybrid database. C,
 637 D) MiR-20a-5p level in H1299 cells transfected miR-20a-5p mimic (C) or miR-20a-5p inhibitor (D)
 638 for 48 h was detected by qPCR, **p < 0.01 vs. NC mimic or NC inhibitor. E) Schematic diagram of
 639 the predicted binding between LINC01518 and miR-20a-5p. F) Partial sequencing results of
 640 LINC01518-WT and LINC01518-Mut. G) The luciferase activity was evaluated by dual-luciferase
 641 reporter assay after H1299 cells co-transfected with LINC01518-WT or LINC01518-Mut along
 642 with NC mimic or miR-20a-5p mimic for 48 h, **p < 0.01 vs. NC mimic. H, I) The expression of
 643 miR-20a-5p was examined by qPCR after H1299 cells stimulated with IL-17 (50 ng/ml) for 1 h, 2 h,
 644 3 h, 6 h. (H), or transfected with pcDNA3.1 or pcDNA3.1/LINC01518 for 48 h, or shCTR and
 645 shLINC01518 for 48 h plus IL-17 for 3 h (I). All data were shown as means $\pm$ SE (n=3), **p < 0.01
 646 vs. 0 h or pcDNA3.1, $\Delta\Delta$ p < 0.01 vs. shCTR, $\Delta\Delta$ p < 0.01 vs. shCTR+IL-17

647

648 **Figure 4.** Effects of miR-20a-5p expression or inhibition and LINC01518 plus miR-20a-5p co-
 649 expression on H1299 cell proliferation. A-C) H1299 cells were respectively transfected with NC
 650 mimic, miR-20a-5p mimic, NC inhibitor and miR-20a-5p inhibitor for 48 h or 8 d, the cell
 651 proliferation level and colony number were checked by CCK8 (A), EdU (B, Magnification $\times 200$)
 652 and colony formation (C) assays, **p < 0.01 vs. NC mimic, Δ p < 0.05, $\Delta\Delta$ p < 0.01 vs. NC inhibitor.
 653 D-F) H1299 cells were transfected with pcDNA3.1, pcDNA3.1/LINC01518, or co-transfected with
 654 pcDNA3.1/LINC01518 plus NC mimic, or miR-20a-5p mimic for 48 h or 8 d, the cell proliferation
 655 and colony number were measured by CCK8 (D), EdU (E, Magnification $\times 200$) and colony
 656 formation (F) tests. Data were presented as means $\pm$ SE (n=3), **p < 0.01 vs. pcDNA3.1, $\Delta\Delta$ p < 0.01
 657 vs. pcDNA3.1/LINC01518+NC mimic

658

659 **Figure 5.** Prediction and identification of target gene that can bind to miR-20a-5p, and the change
 660 of IL-17-induced E2F1 as well as effects of miR-20a-5p expression on E2F1 production. A) The

661 predicted potential target genes that can bind to miR-20a-5p and their intersection by StarBase,
662 miRDB, mirDIP and TarBase databases were showed by Venn diagram. B) The expression levels of
663 E2F1, ARHGAP12, TSG101, CDKN1A in 483 NSCLC tissues and 347 paracancer tissues were
664 analyzed by GEPIA database. C) The correlation between the expression of E2F1, ARHGAP12,
665 TSG101 or CDKN1A and overall survival of 1925 NSCLC patients were analyzed by Kaplan-
666 Meier Plotter database. D, E) The mRNA (D) and protein (E) levels of E2F1, ARHGAP12, TSG101
667 and CDKN1A in H1299 cells transfected with NC mimic or miR-20a-5p mimic for 48 h were
668 detected by qPCR or WB. $**p < 0.01$ vs. NC mimic. F) The binding site of miR-20a-5p to E2F1
669 was showed by StarBase database. G) The expression of E2F1 in H1299 cells treated with IL-17
670 (50 ng/ml) for 1 h, 2 h, 3 h, 6 h and 12 h was examined by WB, $*p < 0.05$, $**p < 0.01$ vs. 0 h. H, I)
671 The mRNA (H) and protein (I) of E2F1 were measured by qPCR and WB in H1299 cells
672 transfected with NC mimic, miR-20a-5p mimic, or NC inhibitor, miR-20a-5p inhibitor for 48 h.
673 Data were shown as means $\pm$ SE (n = 3), $**p < 0.01$ vs. NC mimic, $\Delta\Delta p < 0.01$ vs. NC inhibitor
674

675 Figure 6. Effects of expressed and silenced LINC01518 or E2F1 gene on E2F1 induction or cell
676 proliferation and LINC01518 or miR-20a-5p expression. A, B) H1299 cells were transfected with
677 pcDNA3.1, pcDNA3.1/LINC01518 for 48 h or shCTR, shLINC01518 for 48 h plus IL-17 for 3 h,
678 the E2F1 mRNA (A) and protein (B) were examined by qPCR and WB, $**p < 0.01$ vs. pcDNA3.1,
679 $\Delta\Delta p < 0.01$ vs. shCTR, $^{##}p < 0.01$ vs. shCTR+IL-17. C-E) H1299 cells were transfected with
680 pcDNA3.1, pcDNA3.1/E2F1 for 48 h or shCTR, shE2F1 for 48 h followed by IL-17 for 48 h or 8 d,
681 the cell proliferation and colony number were estimated by CCK8 (C), EdU (D) and colony
682 formation (E) assays, $**p < 0.01$ vs. pcDNA3.1, $\Delta\Delta p < 0.01$ vs. shCTR, $^{##}p < 0.01$ vs. shCTR+IL-
683 17. F-H) H1299 cells were transfected with NC mimic, miR-20a-5p mimic, or co-transfected with
684 miR-20a-5p mimic, pcDNA3.1 or pcDNA3.1/E2F1 for 48 h or 8 d, the cell proliferation and colony
685 number were observed by the same tests, $**p < 0.01$ vs. NC mimic, $\Delta\Delta p < 0.01$ vs. miR-20a-5p
686 mimic+pcDNA3.1. I) H1299 cells were transfected with pcDNA3.1, pcDNA3.1/E2F1 for 48 h or
687 shCTR, shE2F1 for 48 h plus IL-17 for 3 h, the RNA of LINC01518 and miR-20a-5p was measured
688 by qPCR, $**p < 0.01$ vs. pcDNA3.1, $\Delta\Delta p < 0.01$ vs. shCTR. The photograph from EdU
689 (Magnification $\times 200$) and colony formation assay was showed, and data exhibited as means $\pm$ SE
690 (n=3).

691
692 **Figure 7.** LINC01518 can enhance mouse xenograft tumor growth, cell proliferation and relative
693 parameter change. A) Photographs of excised tumors from BALB/c node mice (5/group) were
694 showed in Lv-empty, Lv-LINC01518, Lv-shCTR+IL-17 groups, Lv-shLINC01518+IL-17. B, C)

695 Average tumor volume and weight of tumors in each group. D) Number of Ki67 cells in tumor
 696 tissue sections in each group was displayed by IHC (scale bars=100 μ m). E, F) The RNA level of
 697 LINC01518 and miR-20a-5p in tumor tissues was measured by qPCR. G) The protein expression
 698 of E2F1 in tumor tissues was detected by WB. * $p < 0.05$, ** $p < 0.01$ vs. Lv-empty, $\Delta p < 0.05$, $\Delta\Delta p$
 699 < 0.01 vs. shCTR+IL-17, and the data presented as means $\pm$ SE (n=5). H) A putative scheme of the
 700 mechanism about IL-17-induced NSCLC cell proliferation. LINC01518 in H1299 cytoplasm is
 701 upregulated by IL-17 binding to IL-17RA. In the process, elevated LINC01518 as a ceRNA can
 702 inhibit miR-20a-5p expression by sponging it, enhancing cell proliferation via downregulated miR-
 703 20a-5p and secondary increased E2F1. These findings reveal that LINC01518/miR-20a-5p/E2F1
 704 axis contributes to IL-17-induced H1299 cell proliferation.

Fig. 1 [Download full resolution image](#)




Fig. 2 [Download full resolution image](#)




Fig. 3 [Download full resolution image](#)




Fig. 4 [Download full resolution image](#)




Fig. 5 [Download full resolution image](#)




Fig. 6 [Download full resolution image](#)




Fig. 7 [Download full resolution image](#)

